Skip to content
Question
What will a month cost?
Read
6 min
Updated
October 2026

Sermorelin Tablets: What the Oral Form Costs Against the Injection

The monthly price of compounded sermorelin tablets beside the drop under the tongue and the injection, why a pharmacy may make a tablet when the approved product was a shot, and what a swallowed peptide is up against.

ByDerek MossPricing analystPublished Updated

A month of sermorelin tablets runs a typical $199 from sellers that publish a price. The injection runs $189. The tablet is the newer listing of the three, and the thinnest. The sermorelin price board carries every seller behind these figures.

What identifies it

Swallowed tablet
Instructions say to swallow
Under the tongue
Instructions say to dissolve under the tongue
Injection
Instructions specify injection

Historical GEREF product

Swallowed tablet
Not a GEREF dosage form
Under the tongue
Not a GEREF dosage form
Injection
Both GEREF products were injections

What a matching price proves

Swallowed tablet
Cost only
Under the tongue
Cost only
Injection
Cost only

What to confirm

Swallowed tablet
Formulation and evidence for that route
Under the tongue
Formulation and evidence for that route
Injection
Quantity, usable supply and dispensing pharmacy
Compare the route before comparing the price. GEREF history: FDA's 2013 determination. Product instructions determine the route; prices do not establish clinical equivalence.
Compounded sermorelin, per month, by route, October 2026
Tablet (swallowed)Under the tongueInjection
Lowest published month$119$99$90
Typical (median) month$199$170$189
Highest published month$279$299$449
Sellers publishing a month1524160
Compounded sermorelin, per month, by route, October 2026. Computed from every tracked seller that publishes a monthly figure for that route, each counted once at its lowest month.

The spread inside each column is wider than the gap between columns. That is the practical point: the route matters less to the bill than which seller writes it. The sermorelin cost guide breaks a single month into its parts.

Why a pharmacy may make a sermorelin tablet at all

Federal law lets a pharmacy compound from a bulk substance in three cases[1]. One of them is a substance that is a component of a drug the agency has approved[1].

Sermorelin qualifies through GEREF. FDA determined on March 4, 2013 that GEREF was not withdrawn from sale for reasons of safety or effectiveness[2].

That condition names a substance, not a route. That criterion alone does not certify a particular pharmacy or formulation. Other section 503A requirements still apply[4]. More on the status is in is sermorelin FDA approved.

What the approved product actually was

Both GEREF applications were injections[2]. One covered 0.5 mg and 1.0 mg base per vial, under NDA 20-443[2]. The other covered 0.05 mg base per ampule, under NDA 19-863[2].

Their holder discontinued both in 2008 and asked FDA to withdraw the applications[2]. Neither GEREF approval covered a tablet.

One more condition of the law matters here. A pharmacy may not regularly compound copies of a commercially available drug product[1]. No sermorelin product is commercially available to copy.

What a swallowed peptide is up against

Peptides are unstable in the gut. A 2025 review describes rapid breakdown by digestive enzymes and acid[3]. Absorption is poor because the molecules are large and water-loving[3].

The mouth is the alternative that route claims. The review notes the lining there is well supplied with blood and skips first-pass liver metabolism[3].

It also names the costs of that shortcut. The lining limits what crosses, saliva washes the dose away, and enzymes in saliva break peptides down[3].

The documented September 20, 2026 PubMed search found no human oral-dosing study. It searched sermorelin with oral, tablet, sublingual, troche and buccal terms. That dated search cannot establish that every later study is absent. It does not support treating oral and injected doses as equivalent.

Questions worth asking before the first refill

  • Is the tablet swallowed or held under the tongue, and for how long?
  • How many milligrams per tablet, and how many tablets a month?
  • Does the quoted price include the consult, and what does month two cost?

The last one is where most of the money moves. Turning a vial or bottle into a per-month figure is set out in how long a sermorelin vial lasts. The visit itself is covered in sermorelin prescription.

FAQ

4 questions

Are sermorelin tablets cheaper than sermorelin injections?

This page computes both from every tracked seller that publishes a monthly price, and the gap between the two routes is smaller than the spread inside either one. Which seller writes the prescription moves the bill more than which route it is for.

Is there an FDA-approved sermorelin tablet?

No. The two approved sermorelin products, both sold as GEREF, were injections under NDA 20-443 and NDA 19-863, and both were discontinued in 2008. A compounded tablet is not an approved product.

Why can a pharmacy compound sermorelin as a tablet?

Federal law allows compounding from a bulk substance that is a component of an approved drug. That is one condition, not a certification of a particular pharmacy or tablet. Other section 503A and applicable state requirements still apply.

Do sermorelin tablets work as well as the injection?

The documented September 2026 search found no human oral-dosing study. That finding does not establish equivalence with an injection or rule out later research. A 2025 delivery review describes peptides being broken down rapidly by digestive enzymes and acid, and absorbed poorly because of their size and water affinity.

Sources

4 cited
  1. [1]United States Code (2024). 21 U.S.C. 353a, Pharmacy compounding Office of the Law Revision Counsel. Source
  2. [2]Food and Drug Administration (2013). Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness Federal Register, 78 FR 14095. Source
  3. [3]Amer AA, Bingle L, Elkordy AA, Chaw CS (2025). Overcoming Oral Cavity Barriers for Peptide Delivery Using Advanced Pharmaceutical Techniques and Nano-Formulation Platforms Biomedicines. PMID 41301828
  4. [4]Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act FDA; accessed October 2026. Source